News

Merck & Co., Inc. (MRK) Needs To Move On From Talking About Its Animal Division, Says Jim Cramer
We recently published 13 Stocks That Jim Cramer Recently Talked About. Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer recently discussed.
Fierce Pharma1d
Merck will lay off 6,000, reducing workforce by 8% in cost-cutting purge
Merck will reduce its workforce by approximately 6,000 employees in “some areas of our global workforce,” the New Jersey ...
Fierce Biotech1d
Instil's licensed PD-L1xVEGF bispecific shows promise in China, instilling hope for upcoming US test
A PD-L1xVEGF bispecific antibody from China’s ImmuneOnco Biopharmaceuticals has shown early promise in shrinking lung tumors, ...
BioPharma Dive3d
Merck plans spending shift to boost business beyond Keytruda
Facing an end to Keytruda's market exclusivity, the company will cut $3 billion in costs that it plans to redeploy in support ...
Crain's New York Business3d
Merck to slash $3B in costs as patent cliff for hallmark cancer med nears
Merck is slashing $3 billion from its annual spending as it braces for off-brand competition to its cancer drug Keytruda, the ...
Irish Examiner on MSN3d
MSD plans $3bn cuts amid competition for Irish-manufactured cancer drug Keytruda
MSD is slashing $3bn (€2.59bn) from its annual spending as it braces for off-brand competition to its Irish-manufactured ...
Merck plans $3B annual cost cuts as Keytruda faces patent cliff
Merck (MRK) is cutting $3 billion from its annual expenses as it prepares for generic competition to its blockbuster cancer drug, Keytruda.